MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517061710 A) filed by Vetmab Biosciences, Inc., San Diego, on June 27, for 'anti-il23 and anti-tnf? antibodies.'
Inventor(s) include Zhan, Hangjun.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "Provided are various embodiments relating to caninized, felinized, or equinized antibodies that bind canine, feline, and/or equine IL23 and/or TNFa, including bispecific antibodies that bind to both IL23 and TNFa. Such antibodies can be used alone or in combination in methods to treat canine, feline, and/or equine subjects with inflammatory conditions, such as inflammatory conditions in canines and felines, such as inflammatory bowel disease (IBD), osteoarthritis, and gastroenteritis."
The patent application was internationally filed on Dec. 14, 2023, under International application No.PCT/US2023/084003.
Disclaimer: Curated by HT Syndication.
